Design Considerations for Clinical Investigations of Osteoporosis

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1597-1620

  Heaney, Robert P ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650786038     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50069-0     Document Type: Chapter

References (50)

1. Elementary Medical Statistics 1963, W. B. Saunders, Philadelphia. 2nd. D. Mainland (Ed.).
2. Gardner M.J., Altman D.G. Statistics with Confidence 1989, British Medical Journal, London.
3. Schlesselman J.J. Case-Control Studies. Design, Conduct, Analysis 1982, Oxford University Press, New York.
4. Pocock S.J. Clinical Trials. A Practical Approach 1983, John Wiley & Sons, New York.
5. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer, 1976, 34:585-612.
6. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Annals Int Med, 1991, 115:455-456.
7. Stegman M.R., Heaney R.P., Recker R.R., Travers- Gustafson D., Leist J. Velocity of ultrasound and its association with fracture history in a rural population. Am J Epidemiol, 1994, 139:1027-1034.
8. Cooper C., Atkinson E.J., O'Fallon W.M., Melton L.J. 1985- 1989. J Bone Miner Res, 1992, 7:221-227.
9. Lahey F.H., Hare H. Malignancy in adenomas of the thyroid. JAMA, 1951, 145:689-695.
10. Lafferty F.W., Fiske M.E. Postmenopausal estrogen replacement: A long-term cohort study. Am J Med, 1994, 97:66-77.
11. Kochersberger G., Buckley N.J., Leight G.S., Martinez S., Studenski S., Vogler J. K. W. Lyles, What is the clinical significance of bone loss in primary hyperparathyroidism? Arch Intern Med, 1987, 147:1951-1953.
12. 21 Code of Federal Regulations. Ch. 1, 314.126 (4/1/89 edition).
13. Wolf S. The pharmacology of placebos. Pharmacol Rev, 1959, 11:689-704.
14. Beecher H.K. The powerful placebo. JAMA, 1955, 159:1602-1606.
15. Goodwin J.S., Goodwin J.M., Vogel A.V. Knowledge and use of placebos by house officers and nurses. Ann Intern Med, 1979, 91:106-110.
16. Feinstein A.R. Epidemiologic analyses of causation: The unlearned scientific lessons of randomized trials. J Clin Epidemiol, 1989, 42:481-489.
17. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ, 2003, 326:469-474.
18. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation. JAMA, 2005, 293:2257-2264.
19. Grant A.M. for Group, Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin DRECORD): A randomized placebo-controlled trial. Lancet, 2005, 365:1621-1628.
20. Dowd R., Recker R.R., Heaney R.P. Study subjects and ordinary patients. Osteoporos Int, 2000, 11:533-536.
21. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., Wu A.W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA, 2005, 294:716-724.
22. Korn E.L., Baumrind S. Randomized clinical trials with clinician-preferred treatment. Lancet 1991, 337:149-152.
23. Veatch R.M. Justice and research design: The case for a semi-randomization clinical trial. Clin Res, 1983, 31:12-22.
24. Trochim W.M.K. Research Design for Program Evaluation: The Regression-Discontinuity Approach. Sage 1984, Beverly Hills, CA.
25. Farley S.M., Wergedal J.E., Farley J.R., Javier G.N., Schulz E.E., Talbot J.R., et al. Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density. Osteoporosis Int, 1992, 2:213-218.
26. Heaney R.P. Is the paradigm shifting?. Bone 2003, 33:457-465.
27. Chapurlat R.D., Palermo L., Ramsay P., Cummings S.R. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int, 2005, 16:842-848.
28. Heaney R.P. The bone remodeling transient: Implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res, 1994, 9:1515-1523.
29. Heaney R.P. En recherche de la difference (P < .05). Bone Miner 1986, 1:99-114.
30. Heaney R.P. BMD: The problem. Osteoporos Int, 2005, 16:1013-1015.
31. Prentice A., Parsons T.J., Cole T.J. Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr, 1994, 60:837-842.
32. Carter D.R., Bouxsein M.L., Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res, 1992, 7:137-145.
33. Smith R.W. Femoral expansion in aging women: Implications for osteoporosis and fractures. Science 1964, 145:156-157.
34. Arnold J.S. External and trabecular morphologic changes in lumbar vertebrae in aging. In Progress in Methods of Bone Mineral Measurement 1970, 352-410. U.S. Department of Health, Education and Welfare, Washington, D.C. G.D. Whedon, J.R. Cameron (Eds.).
35. Ericksen M.F. Some aspects of aging in the lumbar spine. Am J Phys Anthropol, 1976, 45:575-580.
36. Matkovic V., Jelic T., Wardlaw G.M., Ilich J.Z., Goel P.K., Wright J.K., Andon M.B., Smith K.T., Heaney R.P. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. J Clin Invest, 1994, 93:799-808.
37. Israel H. Continuing growth in the human cranial skeleton. Arch Oral Biol, 1968, 13:133-137.
38. Susanne C. Ageing, continuous changes of adulthood. In Human Physical Growth and Maturation. Methodologies and Factors 1979, 161-175. Plenum Press, New York. F.E. Johnston, A.F. Roche, C. Susanne (Eds.).
39. Heaney R.P., Barger-Lux M.J., Davies K.M., Ryan R.A., Johnson M.L., Gong G. Bone dimensional change with age: Interactions of genetic, hormonal and body size variables. Osteoporos Int, 1997, 7:426-431.
40. Gilsanz V., Gibbens D.T., Roe T.F., Carlson M., Senac M.O., Boechat M.I., Huang H.K., Schulz E.E., Libanati C.R., Cann C.C. Vertebral bone density in children: Effect of puberty. Radiol, 1988, 166:847-850.
41. Willett W. Nutritional Epidemiology 1998, Oxford University Press, New York. 2nd.
42. Vieth R Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr, 1999, 69:842-846.
43. Armas L.A.G., Hollis B.W., Heaney R.P. Vitamin D is much less effective than vitamin D in humans. J Clin 3 Endocrinol Metab 2004, 89:5387-5391.
44. Charles P. Metabolic bone disease evaluated by a combined calcium balance and tracer kinetic study. Danish Med Bull, 1989, 36:463-479.
45. Heaney R.P. Nutrient effects: Discrepancy between data from controlled trials and observational studies. Bone, 1997, 21:469-471.
46. Levine R.J. Placebo controls in clinical trials of new therapies for osteoporosis. J Bone Miner Res, 2003, 18:1154-1159.
47. Ellenberg S.S. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J Bone Miner Res, 2003, 18:1121-1124.
48. Watts N.B. Is it ethical to use placebos in osteoporosis clinical trials?. Curr Osteoporos Rep 2004, 2:31-36.
49. Silverman S., Cummings S., Watts N. Recommendations for the clinical evaluation of agents for treatment of osteoporosis. J Bone Miner Res 2007, in press.
50. Barrett J.A., Baron J.A., Beach M.L. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int, 2003, 14:889-894.